Navigation Links
Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Date:12/10/2012

BOULDER, Colo., Dec. 10, 2012 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced positive data for ARRY-520 and ARRY‑614 at the 2012 Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.  

(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

New results presented at the meeting for ARRY-520 in addition to those described in the abstracts published by ASH in early November included:

  • Overall survival of 19 months and progression free survival of 3.7 months were observed in multiple myeloma patients taking ARRY-520 alone
  • A clinical benefit rate (≥MR) of 50% was observed in heavily pre-treated (median 10 prior regimens) multiple myeloma patients taking ARRY-520 plus dexamethasone who were selected for low AAG levels 
  • Initial signs of clinical activity were observed in the ongoing ARRY-520+Kyprolis® (carfilzomib) combination trial: 56% clinical benefit rate (≥MR)

In a Phase 2 trial with ARRY-520 in patients with triple-refractory multiple myeloma and a median number of 10 prior treatment regimens, ARRY-520 plus low-dose dexamethasone demonstrated a 22% overall response rate (≥ partial response, or PR), with manageable safety. The most common drug-related adverse events include myelosuppression, fatigue and mucosal inflammation. This response rate is comparable to the response rates reported in pomalidomide and Kyprolis studies, which included patients with only half the number of median prior treatment regimens.  

As presented at ASH, researchers found that AAG (acute phase protein alpha-1-acidic glycoprotein) may be a biomarker enabling better patient selection for response to ARRY-520.  A related abstract asse
'/>"/>

SOURCE Array Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
2. John A. Orwin Joins Array BioPharma Board Of Directors
3. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
4. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
5. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
6. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
7. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
8. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
9. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
10. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
11. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... 23, 2012 SiREM ( www.siremlab.com ) and ... signing of a Sales Agency Agreement between the ... Tersus Environmental will market, promote and sell SiREM,s ... as well as Gene-Trac® molecular testing services and ...
... Mich. and AMSTERDAM, Feb. 23, 2012   Rubicon ... sample-specific pre-analytical processes to improve the capabilities ... platforms, today announced a clinical supply agreement ... TransPLEX® whole genome RNA amplification technology.  Agendia ...
... Inc. (OTCBB: AMBS), a biotechnology company developing MANF, ... Gerald E. Commissiong, President and CEO, will present ... National Investment Banking Association (NIBA) conference on Thursday, ... Pavillon Hotel in New Orleans, LA. Mr. Commissiong ...
Cached Biology Technology:Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 3Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans 2
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
(Date:4/17/2014)... hundred births, Down syndrome - or trisomy 21 - ... It results from a chromosomal abnormality where cells of ... (1% of the human genome). A study conducted by ... Genetic Medicine and Development at the University of Geneva ... shed light on how the extra chromosome 21 upsets ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... PHILADELPHIA People with the heritable disorder of the ... develop basal cell carcinoma of the skin may have ... According to results of a placebo-controlled, randomized, double-blind, Phase ... inhibiting the development of basal cell carcinomas in a ...
... being recognized for devising a new way to study a ... investigating its role in the communication of important genetic messages ... Last year, the team, led by J. Andrew Hockert, at ... Health Science Center School of Medicine, put in its crosshairs ...
... HILL Bacteria can swim, propelling themselves through fluids using ... strolling along solid surfaces using little fibrous legs called pili. ... establish the infections such as meningitis that cause ... Now researchers at the University of North Carolina at Chapel ...
Cached Biology News:Celebrex inhibited the burden of skin cancer in high-risk patients 2Researchers pin down long-elusive protein that's essential to 'life as we know it' 2Researchers pin down long-elusive protein that's essential to 'life as we know it' 3A single atom controls motility required for bacterial infection 2A single atom controls motility required for bacterial infection 3
... the cost-effective solution for entry level imaging ... research imaging tasks, MetaVue enables time lapse, ... analysis. Compatibility with MetaMorphs extensive and ... has the power to drive motorized microscopes, ...
... for microRNA expression profiling ,miRCURY ... Locked Nucleic Acid (LNA) technology to provide ... short microRNA (miRNA) targets. miRCURY LNA Arrays ... RNA (no need for microRNA enrichment) labeled ...
... XL extends the MSn performance of the ... tools to generate extensive structural information for ... , Multiple dissociation techniques (PQD, ETD, ... unpredicted metabolites , Fast polarity switching for ...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Biology Products: